Quality of life impacts from rotavirus gastroenteritis on children and their families in the UK |
| |
| Affiliation: | 1. Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK;2. Schools of Clinical Sciences & Cellular & Molecular Medicine, University of Bristol, Bristol, UK;3. Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK;1. Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf and Schön Klinik Hamburg-Eilbek, Hamburg, Germany;3. Israelitisches Krankenhaus, Hamburg, Germany;4. Department of Gastroenterology and Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;6. Department of Biostatistics and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;5. Department of Psychosomatic Medicine and Psychotherapy, Charité University Medical Center, Berlin, Germany;1. Department of Clinical Epidemiology, Communicable Disease Center, Tan Tock Seng Hospital, Singapore;2. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;3. Faculty of Science, Technology and Engineering, La Trobe University, Melbourne, Australia;4. Vigilance Branch, Health Products Regulation Group, Health Sciences Authority, Singapore;5. Department of Pediatric Medicine, KK Women''s and Children''s Hospital, Singapore;1. Vaccine and Immunisation Research Group (VIRGo), Murdoch Childrens Research Institute and Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia;2. School of Paediatrics and Child Health, University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Princess Margaret Hospital for Children, Perth, Australia;3. Vaccinology and Immunology Research Trials Unit (VIRTU), Women''s and Children''s Hospital, School of Paediatrics and Reproductive Health and Robinson Research Institute, The University of Adelaide, Adelaide, Australia;4. Queensland Paediatric Infectious Diseases Laboratory (Qpid), Queensland Children''s Medical Research Institute, Royal Children''s Hospital, University of Queensland, Brisbane, Australia;5. Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA;6. Novartis Vaccines and Diagnostics S.r.l., Siena, Italy;1. Kantar Health s.r.o., Prague, Czech Republic;2. Department of Pediatrics, the Center of Postgraduate Medical Education, Warsaw, Poland;3. Department of Pediatrics, Clinical Center, University of Debrecen, Debrecen, Hungary;4. Department of Epidemiology of Medical Faculty, Charles University, Pilsen, Czech Republic;5. GSK Vaccines, Wavre, Belgium;6. Faculty of Health Care, Alexander Dubček University of Trenčín, Trenčín, Slovakia;1. Sanofi Pasteur, Toronto, Ontario, Canada;2. University of Toronto Faculty of Pharmacy, Toronto, ON, Canada;3. Creativ-Ceutical Ltd, London, UK;4. Creativ-Ceutical SARL, Paris, France;5. Sanofi Pasteur, Swiftwater, PA, USA;6. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA |
| |
| Abstract: | AimsRotavirus vaccines (RV) are safe and effective but demand significant investment of healthcare resource. In countries with low mortality due to rotavirus, a key component to assessing cost-effectiveness is quantifying the Health Related Quality of Life (HRQoL) lost due to rotavirus acute gastroenteritis (RVAGE).MethodsFamilies with children less than six years old with gastroenteritis were recruited from attendees to Bristol Children's Hospital Emergency Department. Stools were tested for viral causes of gastroenteritis. Children's HRQoL was assessed at presentation using Health Utilities Index 2 (HUI2) with visual analogue scale (VAS). The effect of the child's illness on the HRQoL of up to two adult carers was assessed using EQ-5D-5L. Families completed a daily symptom diary to assess time to recovery and within-family transmission.Results127 families consented to take part, 84(65%) had rotavirus as the cause of illness. At the time of attendance, mean paediatric HRQoL with RVAGE was 0.74(HUI2) and 0.42(VAS). Primary/secondary carer's HRQoL was 0.68/0.80 (EQ5D) or 0.70/0.79 (VAS). The mean number of QALYs lost due to RVAGE was 3.1–3.5 per thousand children and 7.7–8.7 per thousand family units.In 52% of RVAGE families at least one other member developed a secondary case of gastroenteritis. For working parents, 69% missed work, for a mean of 2.8 days (95% CI 2.3–3.4).ConclusionsWe have found the HRQoL loss associated with RVAGE in children and their carers to be significantly higher than estimates used for all RV medical attendances in UK cost-effectiveness calculations. |
| |
| Keywords: | Rotavirus Quality of life Great Britain Rotavirus vaccines Economic evaluation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
